Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
NCT05823480 · City of Hope Medical Center · PHASE1 · withdrawn · last registry update 2024-09-19 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawn -ctms” | Open Targets' class: uncategorised | Registry record, City of Hope Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD47 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-04Results posted on the registry: Gilead Sciences, Magrolimab + Venetoclax (NCT05079230)
- 2025-04-04Also stopped (terminated): Gilead Sciences, Magrolimab + Venetoclax (NCT05079230)
- 2025-02-05Results posted on the registry: Gilead Sciences, Magrolimab + Venetoclax (NCT04778397)
- 2025-02-05Also stopped (terminated): Gilead Sciences, Magrolimab + Venetoclax (NCT04778397)
- 2024-11-27Also stopped (terminated): ALX Oncology Inc., evorpacept + venetoclax (NCT04755244)
- 2024-04-11Also stopped (withdrawn): Novartis Pharmaceuticals, Sabatolimab + Magrolimab (NCT05367401)
- 2024-02-12Also stopped (withdrawn): Uwe Platzbecker, Magrolimab + 7+3 (NCT05829434)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision